Folate deprivation enhances invasiveness of human colon cancer cells mediated by activation of sonic hedgehog signaling through promoter hypomethylation and cross action with transcription nuclear factor-kappa B pathway

Tz-Ping Wang1, Shu-Han Hsu1, Hsin-Chun Feng1 and Rwei-Fen S.Huang1,2,3

1Department of Nutritional Science and 2Ph.D. Program in Nutrition and Food Science, Fu Jen Catholic University, Xinzhuang, Taiwan, Republic of China
2To whom correspondence should be addressed. Department of Nutritional Science and Ph.D. Program in Nutrition and Food Science, Fu Jen Catholic University, Xinzhuang, Taiwan, Republic of China. Tel: +886 2 29021215; Fax: +886 2 29021215; Email: 034825@mail.fju.edu.tw

Low folate status is well recognized as one of the metabolic stressors for colorectal cancer carcinogenesis, but its role in colon cancer invasion remains unknown. Activation of the Sonic hedgehog (Shh) signal in interaction with the transcription nuclear factor-kappa B (NF-κB) pathway is crucial for cancer aggressiveness. The aims of this study were to investigate whether and how folate deprivation promotes invasion by colon cancer cells in relation to Shh signaling and NF-κB pathway activation. Cultivation of epithelial colon cancer-derived cells (HCT116) in folate-deficient (FD) medium enhanced cellular migration and invasion, in correlation with epithelial–mesenchymal transition (EMT) associated with Snail expression and E-cadherin suppression, increased production of β1 integrin and increased proteolysis by matrix metalloproteinase 2. Blockade of Shh signaling by cycloamine (CYC) or of NF-κB activation by BAY abolished FD-enhanced EMT and invasion by HCT116 cells. FD cells had 50–80% less intracellular folate, associated with aberrant hypomethylation of the Shh promoter, than control cells, and increased binding of nuclear NF-κB subunit p65 to the Shh promoter region, which coincided with increased Shh expression and protein production of Shh ligand; in addition, the FD-induced Shh signaling targeted Gli1 transcription activator as well as Pch receptor. The FD-induced Shh induction and activated signaling were blocked by NF-κB inhibitor BAY. Blockade of Shh signaling abrogated FD-promoted NF-κB activation measured by 15ox degradiation and by target gene TNFα expression. Taken together, these findings demonstrate that folate deprivation enhanced invasiveness of colon cancer cells mediated by activation of Shh signaling through promoter hypomethylation and cross actions with the NF-κB pathway.

Introduction

Colorectal cancer (CRC) is one of the most lethal malignancies worldwide (1). Therapeutic options for CRC patients with metastatic cancers are limited, and the 5-year survival rate is <5% (2). Although the potential risk factors for CRC metastasis are not well understood, cancer cells acquire metastatic capacity via multistage epithelial–mesenchymal transition (EMT) (3). Alteration of EMT by increased Snail expression, which downregulates E-cadherin, an epithelial cell marker, could cause cancer cells to lose their epithelial junction and begin migration. Mesenchymal cancer cells express intermediate filaments and extracellular matrix components such as matrix metalloproteinase (MMP), enabling them to digest matrix protein for invasion. The adhesion molecule beta-integrin assists cancer cells in distant organ attachment (4). The induction of EMT via the activation of these molecular targets enhances the metastatic potential of cancer cells.

Recent advances show that aberrant activation of hedgehog (Hh) signaling contributes to EMT in the development of invasiveness and metastasis of several cancers (5–8). Hh signaling is activated when the mammalian Hh ligands such as Sonic hedgehog (Shh) or Indian hedgehog (Ihh) binds to its Patched (Pch) receptor to release the repression of the activity of the transmembrane protein Smootherned (Smo) (9). Translocation of Smo into cytoplasm allows activation of the Gli transcription factors. Gli1 is a target gene of Shh signaling, which messenger RNA (mRNA) expression is the reliable marker of pathway activity. Gli1 activates transcription of genes for Hh pathway components such as Shh ligand and Pch1 receptor (10) and EMTr-associate targets (11,12). Overexpression of Gli1 activator in mouse prostate carcinoma cells caused enhanced migration in vitro and lung metastasis in vivo, with induced Snail expression and E-cadherin repression (5). All the effects were inhibited by treatment with the pathway inhibitor cycloamine (Cyc). Studies have revealed that human colon epithelial cancer cells or human colon carcinomas displayed active Hh–Gli signaling, which is critical for tumor recurrence and metastasis (13,14). Chemical blockade of the Hh pathway by Cyc inhibited colon cancer proliferation, tumor growth, EMT progression and metastasis (14,15).

Potential factors that promote the activation of Shh signaling in relation to colon cancer aggressiveness remain largely unknown. It has been proposed that the transcription nuclear factor-kappa B (NF-κB) plays a regulatory role in Hh signaling activation through Shh induction in cancers (16). The NF-κB pathway is the means of oncogenic signaling that orchestrates inflammatory responses, cellular proliferation, carcinogenesis and invasion by human cancer cells (17–20). In human colorectal tumor cells, NF-κB activation by lipopoly-saccharide enhanced cellular adhesion and invasion through integrin 1-dependent mechanisms (21). NF-κB is composed of heterodimers or homodimers of the NF-κB/Rel family of proteins, whose activation is induced by several stimuli to release NF-κB complexes from inhibitory NF-κB (IκB) to translocate into the nucleus, whereas nuclear NF-κB subunit p65 may bind to a specific consensus sequence and regulate the transcription of target genes (22,23). When activated NF-κB p65 bound to the promoter region of the Shh gene, increased Shh expression and protein production promoted the growth of pancreatic cancers (17,24). Shh knockdown in an in vivo model of pancreatic cancer impaired NF-κB-mediated tumor growth (24). NF-κB-mediated activation of Shh signal in monocytes may contribute to pancreatic cancer progression through Shh production (25). In human renal cell carcinoma, the Shh signaling pathway is reactivated to interact with the NF-κB pathway, playing a critical role in tumor growth (26). Whether cross activation of Shh signaling with the NF-κB pathway contributes to colon cancer invasion requires investigation.

Colon cancer patients frequently suffer from folate deficiency due to dietary insufficiency, metabolic stress or clinical etiology such as inflammatory bowel diseases (27–30). Low folate status is well recognized as one of the metabolic stressors for CRC carcinogenesis (27–31). Cellular folate depletion disturbed intracellular one-carbon metabolism and thus the supply of methyl groups, leading to DNA hypomethylation and chromosome instability, in part explaining the carcinogenic action of folate deficiency in colon cancer (32). Whether folate insufficiency with disturbed one-carbon metabolism may predispose colon cancer cells to invasiveness is relatively unknown. Several key pathway elements of Hh signaling contain CpG islands in their promoter regions (33), and overexpression of Shh ligand by...
epigenetic demethylation of its promoter region has recently been reported in primary colorectal carcinoma (34). Promoter hypomethylation is suggested to be an important mechanism regulating constitutive Shh expression in cancer aggressiveness (35). In addition, prolonged folate deprivation induced the expression of invasive-associated genes such as those for NF-kB and for the adhesion molecule integrin 1 in human colon adenocarcinoma cell lines (36). The limited evidence raises the possibility that folate deficiency promotes colon cancer invasiveness through the activation of these two invasive-associated signaling routes.

The aims of this study were to investigate whether and how folate deprivation promotes invasion by colon cancer cells through activation of Shh/NF-kB pathways. We used the HCT116 cell line, which has low invasive capacity, as an in vitro model cell, as it derives from an adenocarcinoma of the colorectal epithelium with adenomatous polyposis coli (APC) tumor suppressor gene mutations and thus mimics an aberrant molecular background in colon cancer lesions. We report, for the first time, that folate deprivation enhanced invasion by colon cancer cells mediated by activation of Shh signaling through Shh promoter hypomethylation and cross actions with NF-kB pathways.

Materials and methods

Materials

Folate (pteroylmonoglutamic acid), methotrexate (MTX), CYC, and McCoy’s 5A medium were purchased from Sigma Chemical (St Louis, MO). RPMI 1640 medium was obtained from Invitrogen (Grand Island, NY). Penicillin, streptomycin, fungizone, trypsin, trypan blue and fetal bovine serum (FBS) came from Gibco Laboratories (Grand Island, NY). Matrigel was purchased from BD Franklin Lakes, NJ). NF-kB inhibitor Bay117082 (BAY), P3K inhibitor LY294002 (LY) and antibodies of NF-kB (IκBα, pIKBα (Ser27), Shh, Gli1, integrin β1, MMP2 and 9 were from Cell Signaling Technology (Boston, MA). Antibodies for β-actin and histone H1 were from Millipore (Temecula, CA) and GencTex (Irvine, CA), respectively. Millicell culture inserts containing a thin-film polycarbonate (PCF) membrane with a pore size of 8 μm were obtained from Millipore (Billerica, MA).

Cell culture

The HCT116 cell line was obtained from the National Development Center of Biotechnology (Taipei, Taiwan). HCT116 cells were maintained as a monolayer culture in McCoy’s 5A medium at 37°C in a humidified 5% CO2 incubator with the medium changed every 3 days. Before the experimental treatment, the cells were adapted to culture in RPMI 1640 medium supplemented with 2.0 g/l sodium bicarbonate, 10% (vol/vol) FBS, 100 U/ml of penicillin and 100 mg/ml of streptomycin. Folate-deprived cells were cultured in folate-deficient (FD) RPMI 1640 medium to deplete intracellular folate levels. To minimize exogenous folate sources, we replaced FBS with dialyzed FBS, which had been dialyzed against phosphate-buffered saline at 4°C for 16 h. As the folic acid antagonist, MTX treatment (100 μg/ml) was used to disrupt intracellular one-carbon metabolism, serving as the alternative folate-deprived control in some of the experiments.

Migration and invasion assays

Migration of HCT116 cells was examined by modified Millicell culture insert. After the inner side of the PCF membrane was precoated with 100 μl matrigel (2 mg/ml) overnight, we measured cellular invasiveness. Cellular migration was measured using the insert without matrigel coating. A cell suspension (5 x 104 cells) was added to each insert. The cells were allowed to migrate or invade for 24 or 48 h at 37°C and 5% CO2. The cells that invaded or migrated through the pores and adhered to the PCF membrane were fixed and dipped in methyl alcohol for 15 min. The PCF membranes were dyed for 1 h with Giemsa stain and then the invaded cells were observed and recorded under the microscope. The results were expressed as the number of invaded cells per microscope field. All experiments were repeated three to six times.

Cancer cell adhesion

HCT116 cell attachment to collagen I was performed as described previously with some modifications (21). Briefly, collagen I (1.5 μg/ml) was coated onto 96-well plates and incubated for 15 h at 4°C. HCT116 cells cultivated in various experimental media at different time periods were passed into the collagen I-coated 96-well plates and incubated in serum-free medium at 37°C in humidified 5% CO2 for 2 h. The plates were washed twice with phosphate-buffered saline to remove unbound cells. Then the absorbance was decided by the MTT colorimetric method.

Gelatin zymography

The activities of MMP-2 and MMP-9 in the conditioned media (serum free) were determined by gelatin zymography. One hour before cultivation of HCT116 cells was terminated at each designated time point, the medium changed to conditioned medium. The conditioned media were collected and centrifuged. The supernatants were then loaded onto sodium dodecyl sulfate–polyacrylamide gels that were polymerized with gelatin at a final concentration of 0.1 mg/ml. After electrophoresis, the gels were renatured in 2.5% Triton X-100 and then incubated in developing buffer (40 mM Tris–HCl buffer, pH 7.4) in the presence of 2 mM CaCl2 and 0.01% NaN3 overnight at 37°C. The gels were then stained with Fast Blue gel staining reagent (Protech, Taipei, Taiwan). The gelatinase activity of MMP2 or MMP9 was then visualized as transparent bands on a blue background.

RNA extraction and real-time reverse transcription–PCR

Total RNA was extracted with an RNAzol Bee-RNA isolation kit. Briefly, 1 μg of each sample was reverse-transcribed in an MMLV Reverse Transcriptase 1st-Strand cDNA Synthesis Kit. Gene transcripts were amplified with specific primers as shown in the Supplementary Table 1, available at Carcinogenesis Online. The cycling conditions included an initial phase of 2 min at 50°C, 10 min at 95°C and then 40 cycles of 10 s at 95°C, 0.5 min at 60°C and 10 s at 72°C. Amplified complementary DNA was quantified using the QuantiTect SYBR Green PCR kit in a LightCycler PCR system.

Western blotting

Whole-cell extraction was conducted using cell lysis buffer (Cell Signaling Technology, Boston, MA) supplemented with 10 mM protease inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride. Protein concentrations were then measured with Bio-Rad protein assay kits (Bio-Rad, Hercules, CA). The protein lysates were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and then transferred onto polyvinylidene difluoride membranes (Whatman, Boston, MA), blocked with phosphate-buffered saline containing 0.2% Tween 20 and 5% non-fat powdered milk and incubated first with antibodies. Bound antibodies were detected using Anti-mouse or anti-rabbit secondary antibody horseradish peroxidase conjugate (Santa Cruz Biotechnology, Santa Cruz, CA), followed by SuperSignal West Femto Chemiluminescent Substrate (Thermo, Rockford, IL) using a UVP BioSpectrum system (Upland, CA).

Enzyme-linked immunosorbent assay of NF-kB activation DNA binding

The TransAM™ NFκB p65 kit (Active Motif, Tokyo, Japan) was used according to the manufacturer’s instructions. A double-stranded DNA sequence containing the NF-kB binding consensus site (5’-GGGACTTCCC-3’) was immobilized to the 96-well plate. Nuclear extracts of the HCT116 cells cultured in each condition were applied to the wells and allowed to bind to the response element. NF-kB DNA binding was detected by the subsequent addition of a primary antibody against p65 and a horseradish peroxidase-conjugated secondary antibody. A colorimetric readout was obtained at 450 nm using a Bio-Rad plate reader.

Analysis of apoptotic and necrotic cells

Cells (1 x 106) were suspended in incubation buffer (10 mMol N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid/NaOH, pH 7.4, 140 mMol NaCl and 5 mMol/ NaCl) containing 1 mg/ml propidium iodide (PI) and a 1:50 dilution of Annexin-V-Fluos labeling solution. The mixed solution was incubated for 15 min on ice. Incubation buffer was added and green (annexin-V stain: apoptotic cells) and red (PI stain: necrotic cells) fluorescence intensities were analyzed on a Coulter EPICS XL-MCL flow cytometer (Coulter, Miami, FL) at 488 nm excitation with a 515 nm bandpass filter for annexin V and a 560 nm filter for PI detection. Cells positive for Annexin-V and negative for PI fluorescence were defined as apoptotic.
Intracellular folate assay

Intracellular folate levels were determined by the method of Horne and Patterson (37). Briefly, cells from control or FD cultures were trypsinized, and intracellular folate was extracted in extraction buffer [20 g/l sodium ascorbate, 50 mMol/l N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid, 50 mMol/l CHES (2-[N-(2-hydroxyethyl) amino]-2-ethanesulfonic acid), 1.4% [3H] mercaptoethanol, pH 7.85]. Upon treatment with chicken pancreas conjugase (vol/vol: 4:1), total intracellular folate content was quantified by microbiological assay using glyceraldehyde-protected Lac-tobacilus casei (ATCC no. 7949) in 96-well microtiter plates. Absorbance was measured at 600 nm in an MRX model ELISA reader (Dynatech Laboratories, West Sussex, UK).

Bisulfite modification of genomic DNA

Genomic DNA was isolated using the standard protocol. Bisulfite modification of genomic DNA was performed in an EpiTect PCR Control DNA Set (Qiagen, Hilden, Germany). This procedure integrates DNA denaturation and bisulfite conversion into one step based on a reaction between cytosine and sodium bisulfite that converts unmethylated cytosines into uracils. Briefly, 1 μg DNA in 20 μl de-ionized water was mixed with CT Conversion Reagent and heated at 95°C for 10 min and then at 64°C for 2.5 h. Binding buffer was added, and the sample was applied to a Zymo-Spin™ IC column for centrifuging at full speed (>10,000 g) for 30 s. The supernatant was incubated in desulfonation buffer for 20 min. Each bisulfited DNA sample was eluted from the column matrix in 10 μl Tris-EDTA buffer and stored at or below –20°C.

Analysis of CpG island methylation status of Shh promoter

The Shh promoter exists as a dense CpG island spanning ~300 bp around the first exon (38). DNA methylation patterns of the CpG islands of the Shh promoter were determined by bisulfite modification of the unmethylated, but not the methylated, cytosines to uracil and subsequent PCR using primers specific to either the methylated or the modified unmethylated DNA. The primers were designed as either ‘M’ primers to detect methylated DNA sequences (forward: 5'-GGGAGAGTTTTGTAGTTGT-3'; reverse: 5'-GGATACCCCTTCTTGCAGC-3') or ‘U’ primers to detect unmethylated sequences (forward: 5'-GGGTGAGAGTTTTGTAGTTGT-3'; reverse: 5'-ACATACCTCTTCCTTACCTTT-3'). The products of the specific-PCR reaction were 131 bp long for unmethylated DNA and 127 bp long for methylated DNA. The conditions for the methylation-specific PCR were an initial denaturation at 95°C for 10 min; 40 cycles of 94°C for 30 s, 54°C for 45 s, 72°C for 45 s, followed by a final extension at 72°C for 10 min. Human placental DNA treated in vitro with SssI methyltransferase was used as a positive control for methylated alleles and DNA from normal lymphocytes as a negative control for methylated alleles. Each PCR reaction was directly loaded into 2% agarose gels, stained with ethidium bromide and visualized under UV illumination.

Statistics

Data were analyzed by Student's paired t-test to determine the statistical significance of differences between the control and folate-deficient groups at P = 0.05.

Results

Folate deprivation and MTX treatment enhanced invasiveness of HCT116 cells

HCT116 cells cultured in FD medium for 24 and 48 h showed greater migration and invasion than control cells (Figure 1A). Migration was increased to 2.0 ± 0.5 after 24 and to 7.0 ± 0.5 after 48 h (P < 0.05; Figure 1B). Invasion of matrigel was increased to 2.8 ± 0.5 and 5.6 ± 0.5, respectively (P < 0.05; Figure 1B). Adhesion was significantly increased too (Figure 1C). As cell viability may compromise the invasive and adhesive phenotype of cancer cells, we further characterized apoptotic and necrotic cellular death (Supplementary Figure 1 is available at Carcinogenesis Online). FD treatment for 24 and 48 h induced apoptosis of up to 10% of cells (AV-positive), compared with 5% of the controls (P < 0.05), without affecting overall necrosis (PI-positive; <5%). To confirm that the enhanced invasion by FD cells was specific to the disturbance of intracellular one-carbon metabolism due to folate depletion, we used MTX, a folic antimetabolite, as the alternative FD control. Treatment of HCT116 cells with MTX for 24 h significantly induced migration, invasion and adhesion (Figure 1A–C). Relative to the controls, FD cultivation of HCT116 cells induced proteolysis by MMP-2 in the pro-form and the active form at 6, 12 and 24 h (P < 0.05; Figure 1D). Activities of MMP-9 showed no response to FD (data not shown). The production of β1 integrin was increased at 12–24 h (P < 0.05; Figure 1E). MTX treatment significantly increased the activities of pro- and processed-MMP-2 and increased the production of β1 integrin (Figure 1D and E). It also promoted apoptosis of 20% and necrosis of 7% (Supplementary Figure 1 is available at Carcinogenesis Online).

Inhibition of Hh signaling and NF-κB pathway abolished FD-induced EMT and invasion by HCT116 cells

Both Hh signaling and the NF-κB pathway are crucial for colon cancer invasion. We investigated their involvement in FD-enhanced invasion by HCT116 cells. Pretreatment of FD cells with CYP to inactivate Hh signaling or with BAY to inhibit NF-κB activation completely abrogated FD-enhanced invasion by HCT116 cells (Figure 2A and B). CYP or BAY treatment did not significantly affect cellular viability during the experiment (data not shown). FD increased expression of Snail and suppressed expression of E-cadherin (Figure 2C and D). CYP or BAY treatment of FD cells abolished FD-enhanced EMT markers and proteolytic MMP-2 activity (Figure 2C–E). The data thus suggest that FD-enhanced EMT and invasion by HCT116 cells was in part, if not all, mediated by activation of Hh signaling and the NF-κB pathway.

Depleted intracellular folate status was associated with aberrant methylation status of the Shh promoter region in FD cells

To investigate how folate depletion may activate Shh signaling, we analyzed both the intracellular folate level and the methylation status of the Shh promoter region. Intracellular folate levels of FD cells dropped significantly by 50% at 6 h, by 60% at 12 h and by 80% at 24 and 48 h (P < 0.05; Figure 3A). As the Shh promoter harbors a dense CpG island spanning ~300 bp around the first exon (38), we analyzed methylation of the promoter region by the bisulfite method and methylation-specific PCR analysis (Figure 3B). In the control cells, the Shh promoter region was partially methylated during 6, 12 and 24 h cultivation. In the FD cells, the methylation status gradually decreased at 12 and 24 h, as shown by the reduced amplification by the M primer (Figure 3B). Hypomethylation of the Shh promoter was complete at 24 h.

Effects of FD on Shh induction and Shh–Gli signaling

To delineate the FD-associated hypomethylation from Shh induction and Hh signaling, we assayed transcript and protein levels of Shh, the key pathway components and target genes of Hh signaling (Figure 4). Transcript levels of Shh were significantly increased to 2.0–2.5× at 6, 12 and 24 h (P < 0.05; Figure 4A). The production of Shh ligand was significantly raised to 2× at 12 and 24 h (P < 0.05; Figure 4B). Simultaneously, transcripts and proteins of transcription factor Gli1, one of the targets of activated Hh signaling, were upregulated to 2–3× at 6–24 h (Figure 4B). To further confirm FD-activated Hh signaling, we assayed expression of another target gene, Ptc1 receptor, and other pathway components, namely Ihh ligand, Smo transducer and Hip repressor. Except for Hip, all target genes and pathway components were upregulated in FD cells (Figure 4C). MTX treatment promoted activation of the Shh–Gli signal via increased production of Shh ligand and effector Gli1 (Figure 4B).

Effects of FD on NF-κB activation associated with increased DNA binding to Shh promoter region

We further investigated whether and how FD-induced Shh signal related to NF-κB activation. Production of the RelA/p65 subunit of NF-κB was first upregulated at 6 h of FD cultivation and remained increased levels at 12 and 24 h (P < 0.05; Figure 5A). Treatment of HCT116 cells with MTX also increased RelA/p65 (P < 0.05). To directly assess the effects of FD-enhanced RelA/p65 on Shh induction, we used an oligonucleotide corresponding to putative NF-κB binding sites within the Shh promoter region (17, 24) to perform EMSA. Relative to the control nuclear extract, 6 h FD cultivation enhanced DNA binding of nuclear NF-κB to the Shh promoter region, as indicated by the increased intensity of the shifted band of the protein–DNA

1160
FD enhances colon cancer invasion by Shh and NF-κB signal

complex (Figure 5B, left panel). Correspondingly, immunobots for RelA performed on nuclear extracts confirmed that the NF-κB protein–DNA complex contained p65 (Figure 5B, super-shift). The shifted band specific to NF-κB binding was identified by competition with unlabeled NF-κB at 100× concentration (cold competition). The unlabeled oligonucleotide effectively competes with binding, leading to the disappearance of the band on the nuclear extracts of the control and FD cells at 24 h (Figure 5C). The competition assay confirmed that the nuclear protein subunits binding to the Shh promoter are specific for the NF-κB consensus binding sequence.

**Fig. 1.** Effects of folate deprivation on invasiveness of HCT116 cells. HCT116 cells at log-growth phase were cultured with control or folate deficient (FD) medium for 6, 12, 24 or 48 h or with control + MTX (100 μg/ml) medium for 24 h. (A) Representative matrigel images of migration and invasion by HCT116 cells. (B) Quantification of invasive or migration cells by counting Coomassie blue-stained cells in 10 fields of each multicell PCF insert. (C) Cancer cell adhesion. (D) Proteolytic activities of MMP-2 and (E) Production of β1 integrin adhesion molecules. The proteolytic activities of MMP-2 were measured by gelatin zymographic assay. β1 Integrin production was assayed by western blot. Data are means ± standard deviations of three to six independent experiments or the percentages of control (means ± standard deviations of three independent experiments). *Compared with respective controls by Student’s t-test at P < 0.05.

Blockade of NF-κB pathway abolished FD-induced Shh induction and Shh–Gli signaling by HCT116 cells

We further investigated whether FD-promoted Shh induction and Shh–Gli signaling depended on NF-κB pathway activation. Pretreatment of HCT116 cells with BAY abrogated FD-promoted transcript and protein levels of the Shh ligand during 6 to 24 h cultivation (Figure 6A and C; some data not shown), which in parallel diminished the response of the FD-induced target gene Gli1 (Figure 6B and C) in Shh signaling. The data suggest that NF-κB pathway activation mediated Shh signaling partially, if not totally, through Shh ligand.
induction in FD cells. To confirm whether the NF-κB-mediated Shh signaling was Shh induction dependent, we tested with CYC as a potent inhibitor of Smo, a Shh-dependent signal transducer. Treatment of FD cells with CYC completely abolished FD promotion of transcript and protein levels of Shh and Hh target genes of Gli1 (Figure 6A–C). It should be noted that CYC treatment of 12 h FD cells significantly reduced the Gli1 transcript levels to below the controls, suggesting that Shh–Gli signaling accounts for the residual Hh activation in the control cells. When FD cultivation reached 24 h, the Gli1 transcript levels of the CYC-treated FD cells had rebounded to the control levels (Figure 6B).

Blockade of Shh signaling differentially affected FD-induced NF-κB pathway activation of HCT116 cells

The next question to ask was whether FD-induced Shh signaling cross-reacted with NF-κB pathway, as previously reported in several cancer cells (26). At transcriptional levels, FD promoted mRNA expression of NF-κB subunit p65 only at 6 h cultivation. BAY or
FD enhances colon cancer invasion by Shh and NFκB signal

Fig. 3. Effects of folate deprivation on intracellular folate status and methylation status of the Shh promoter region in HCT116 cells. HCT116 cells at log-growth phase were cultivated in control (C) or folate deficient (FD) medium for 6, 12, 24 or 48 h. (A) Intracellular folate levels of HCT116 cells. Data are percentages of the control. Values are means ± standard deviations of three independent experiments. * Compared with the control by Student’s t-test at P < 0.05. (B) Representative graph showing the region between –200 and +300 of the Shh 5′-flanking sites. The locations of the primers for methylation-specific (MS) PCR lay in the −68 to −59 bp region. Analysis of CpG island promoter methylation status of the Shh gene by MSP in DNAs of cells cultivated for 6–24 h. The presence of a visible PCR product in lane M indicates the methylated promoter region, and the presence of product in lane U indicates the unmethylated promoter region. Normal human DNA (Control U) and in vitro methylated DNA (Control M) were used as negative and positive controls for methylation, respectively.

Discussion

Because low folate status is well established as a risk factor for CRC carcinogenesis (27–31), we tested the hypothesis that it may lead colon cancer cells to develop aggressiveness. Several lines of evidence indicate that folate deprivation enhanced the invasiveness of HCT116 cells: (i) FD induced upregulated Snail expression and suppressed E-cadherin expression, causing loss of epithelial adhesion and thus promoting migration (39). (ii) FD increased the proteolytic activity of MMP-2, which digested Type I collagen in extracellular matrix, permitting invasion (3). (iii) FD-promoted mRNA expression of b1 integrin (a fibronectin receptor), which supports the attachment of cancer cells to extracellular matrix (40). The FD-induced alteration of EMT molecular markers correlated with low intracellular folate status of colon cancer cells (80% depletion). Previous evidence suggests that low-folate-induced aberrant one-carbon metabolism in colon cancers (27–32) is responsible. Indeed, treatment of HCT116 cells with a folate antimetabolite, MTX, promoted...
Protein production was analyzed by western blot. Data are percentages of the control. Values are means ± standard deviations of three independent experiments. genes of Shh signaling as assayed by RT–PCR. Changes in the specific PCR products were corrected for the corresponding level of GUS.

Abbreviated activation of Hh signaling by dysregulation of Hh ligands such as Shh or downstream components of the Hh–Gli pathway has been shown to be associated with the aggressiveness of cancers (5–8), including colon cancers (13–15). Consistent with these scenarios, we demonstrated that FD promoted aberrant activation of Shh–Gli signaling, which modulated the invasiveness of HCT116 cells. Several studies have reported that HCT116 cells possessed a low residual Hh signal characterized by the absence of Patch mRNA, the absence of Shh ligand (41), low Hh reporter activity (42) and no response to CYC downregulated FD-induced Shh mRNA expression and hypermethylation of its promoter were reported (34). In agreement with the previous studies, we found partial methylation of the Shh promoter region and low residual expression of transcripts and proteins in HCT116 cells. FD depleted the intracellular folate content of HCT116 cells by 50–80%, and this depletion correlated with hypomethylation of the CpG region of the Shh promoter and correspondingly with elevated expression of Shh transcripts and protein. Ihh with a hypermethylated promoter region was not expressed in colon cancer cell lines (34) but was upregulated in FD HCT116 cells. Our preliminary data showed that blockade of transcription by 5-aza-2'-deoxycytidine increased Shh and Ihh expression in colon adenocarcinoma cells, and 5-aza-2'-deoxycytidine treatment of FD colon cancer cells further promoted Shh and Ihh expression (45).

Increased expression of primary CRCs (34) and in microsatellite and chromosomal stable colon cancers (44). Consistent with a low residual Hh signal in some colon cancer cell lines (41–43), absence of Shh mRNA expression and hypermethylation of its promoter were reported (34). In agreement with the previous studies, we found partial methylation of the Shh promoter region and low residual expression of transcripts and proteins in HCT116 cells. FD depleted the intracellular folate content of HCT116 cells by 50–80%, and this depletion correlated with hypomethylation of the CpG region of the Shh promoter and correspondingly with elevated expression of Shh transcripts and protein. Ihh with a hypermethylated promoter region was not expressed in colon cancer cell lines (34) but was upregulated in FD HCT116 cells. Our preliminary data showed that blockade of transcription by 5-aza-2'-deoxycytidine increased Shh and Ihh expression in colon adenocarcinoma cells, and 5-aza-2'-deoxycytidine treatment of FD colon cancer cells further promoted Shh and Ihh expression (45).

The precise nature of FD-induced Shh overproduction and activated Shh signaling in colon cancer cells remains elusive. One plausible mechanism is persistent induction of Shh ligand through hypomethylation of its gene’s promoter region (35). Overproduction of Shh and hypomethylation within the promoter correlated with increased gene expression in primary CRCs (34) and in microsatellite and chromosomal stable colon cancers (44). Consistent with a low residual Hh signal in some colon cancer cell lines (41–43), absence of Shh mRNA expression and hypermethylation of its promoter were reported (34). In agreement with the previous studies, we found partial methylation of the Shh promoter region and low residual expression of transcripts and proteins in HCT116 cells. FD depleted the intracellular folate content of HCT116 cells by 50–80%, and this depletion correlated with hypomethylation of the CpG region of the Shh promoter and correspondingly with elevated expression of Shh transcripts and protein. Ihh with a hypermethylated promoter region was not expressed in colon cancer cell lines (34) but was upregulated in FD HCT116 cells. Our preliminary data showed that blockade of transcription by 5-aza-2'-deoxycytidine increased Shh and Ihh expression in colon adenocarcinoma cells, and 5-aza-2'-deoxycytidine treatment of FD colon cancer cells further promoted Shh and Ihh expression (45). Shh expression and Shh signaling were also induced in MTX-treated HCT116 cells. Taken together, our data confirm the canonical impact of folate deprivation as a one-carbon metabolic stressor that influences aberrant promoter region-specific hypomethylation of Shh pathway components. This role of folate deprivation in hypomethylation of the Shh promoter may contribute in part, if not all, to the activated Hh pathway in FD-enhanced colon cancer invasion. Alternatively, FD promoted the NF-κB activation to contribute to Shh signaling through Shh ligand induction. Enhanced binding of nuclear NF-κB p65 to the Shh promoter with increased transcript levels of Shh was shown in 6 h FD cells, followed by increased Shh protein production at 12 h. Blockage of NF-κB activation by BAY abolished FD-induced transcript levels of Shh and Gli1, a target gene.

**Fig. 4.** Folate deprivation activated Shh induction and Hh signaling. HCT116 cells were cultivated in control, folate deficient (FD) or control + MTX medium (100 μg/ml) for 6, 12 or 24 h. (A) Transcript levels of Shh ligand and Gli1 transcription activator in control or FD HCT116 cells. (B) Production of Shh ligand and Gli activator proteins. ‘MTX’ indicates cells cultivated in control medium + MTX (100 μg/ml) for 24 h. (C) Transcript levels of pathway components and target genes of Shh signaling as assayed by RT–PCR. Changes in the specific PCR products were corrected for the corresponding level of GUS gene in the sample. Protein production was analyzed by western blot. Data are percentages of the control. Values are means ± standard deviations of three independent experiments. *#Compared with the respective controls by Student’s t-test at P < 0.05.
FD enhances colon cancer invasion by Shh and NFκB signal

FD enhances colon cancer invasion by Shh and NFκB signal. The data suggest that Shh ligand is the downstream target of the FD-promoted NF-κB pathway at the transcriptional level in colon cancer cells. Such actions of the NF-κB activation on the Shh signaling pathway, newly identified in FD-colon cancer cells, are in agreement with recent findings that overproduction of NF-κB p65 increased nuclear p65 binding to the Shh promoter in vivo, increasing Shh expression and so mediating pancreatic tumorigenesis and aggressiveness (17,24,25). Interestingly, we found that FD-enhanced NF-κB p65 binding to the Shh promoter region was decreased after 6 h cultivation, whereas NF-κB activity was persistently upregulated by FD-enhanced IκB protein degradation, increased protein levels and its target gene expression of TNFα (Figure 7). This FD-promoted NF-κB activation was consistent with the results of our previous report on human hepatoma cells (46). A substantial variety of mechanisms regulate the DNA-binding activity of various NF-κB homo- and hetero-dimers. The strength and duration of the NF-κB binding to the promoters of target genes may in part, or in total, rely on posttranslational modifications such as acetylation or phosphorylation of the NF-κB complex or relevant histones around NF-κB target genes (47,48). Given that total DNA-binding activity of NF-κB was also decreased after 12 h FD cultivation (Figure 7), when the Shh promoter region started to be hypomethylated by folate deprivation (Figure 3).
and that FD modified phosphorylation of the NF-κB complex (46), our data support the possibility that FD-associated posttranslational modifications and epigenetic regulation may modify NF-κB binding to the Shh promoter region. As characterized in pancreatic cells, there are several putative binding sites for the nuclear NF-κB complex in the CpG island-rich region of the Shh promoter (24; Figure 3). Whether FD-disturbed one-carbon metabolism can elicit nuclear modification of the NF-κB complex or FD-induced epigenetic hypomethylation may modulate DNA binding of NF-κB p65 at all putative binding sites of the Shh promoter required studies.

One of the major findings in the present study is to demonstrate that FD-promoted the Shh signaling and NF-κB activation were under reciprocal regulation. Treatment of HCT116 cells with NF-κB pathway inhibitor abrogated FD-induced overproduction of Shh protein and Gli1 transcription activator, which was due, in part or in full, to the abovementioned transcriptional upregulation. Instead of affecting nuclear translocation and DNA-binding activity of nuclear NF-κB subunit p65 at all putative binding sites of the Shh promoter required studies.

The data suggest that regulation of NF-κB activation by Shh signaling could be compartmentalized in the cytosol, at least, at the IkBα degradation and subject to the FD-associated multistep regulatory process. Although the mechanisms by which FD promotes a positive signaling feedback loop of Shh and NF-κB signaling are not known, it has recently been proposed that Shh signaling acts on multiple upstream regulatory signals of the NF-κB pathway such as the Akt/Erk1/2 pathway in pancreatic tumorigenesis (49) and the RAS/Akt pathway in human melanomas (50). In renal cell carcinoma, both CYC treatment and Smo–Gli1 silencing inhibited the Akt/PI3K pathway as well as NF-κB activation (26). Cross interaction among the PI3K, mitogen-activated protein kinase and Shh pathways in esophageal cancer has been reported (51). Mitogen-activated protein kinase and Akt signaling in cancer cells may regulate the nuclear localization and transcriptional activity of Gli1. Such Akt activation in cultured fibroblasts can potentiate Gli activation by low-level Shh signaling to reinforce the activation of multiple target pathways (52). If that is the case in FD-colon cancer cells, it explains why CYC inhibited FD-induced Gli1 expression at 12 h, but the expression partially recovered even with continuous CYC treatment for 24 h. Given that PI3K/Akt blocker (LY) abrogated the FD-induced NF-κB activation measured by IkBα degradation, the possibility of inducing a positive feedback loop in the PI3K/Akt–NF-κB–Shh pathway to mediate FD-enhanced invasion by colon cancer cells is highly likely. Analysis of the activation status of each signaling pathway in Smo–Gli1–NF-κB or PI3K–Akt-silencing
FD enhances colon cancer invasion by Shh and NFκB signal

FD enhances colon cancer invasion by Shh and NFκB signal

FD-cells should provide additional insights into the reciprocal regulatory mechanisms and the sequential cross actions of these pathways.

In summary, our data identify folate deprivation as the metabolic stressor that enhances EMT and invasiveness of epithelial-adenocarcinoma-derived colon cancer cells. Through Shh promoter hypomethylation and cross-activation of the NF-κB pathway, FD activated Shh induction and Shh–Gli signaling to mediate invasion by colon cancer cells. FD may promote a positive feedback loop in the NF-κB–Shh pathway to reinforce multiple targets of EMT-associated signaling. These mechanisms are subjects for future studies. Clarification of the signal pathways involved as key biomarkers of FD-enhanced colonic cancer aggressiveness is of clinical significance in identifying therapeutic targets of better prognosis for colon cancer patients suffering from folate deficiency due to dietary insufficiency, metabolic stress or clinical etiology such as inflammatory bowel disease.

Supplementary material

Supplementary Table 1 and Figures 1 and 2 can be found at http://carcin.oxfordjournals.org/.

Fig. 7. Effects of blockade of NF-κB pathway or of Shh signaling on folate deficient (FD)-induced activation of NF-κB pathway in HCT116 cells. HCT116 cells were cultivated in control or FD medium with or without 24 h pretreatment with cyclopamine (CYC: 10 μM), Bay117082 (BAY: 3 μM) or LY294002 (LY: 20 μM). (A) Western blot analysis of NF-κB subunit p65 protein. (B) Transcript levels of TNFα as target gene of NF-κB pathway activation. (C and D) Effects of inhibitor treatments on FD-induced NF-κB pathway activation as measured by (C) IkBα degradation and nuclear translocation of NF-κB subunit p65 and (D) NF-κB DNA-binding activity. Proteins of cytosolic extracts (CE) were normalized against actin. Proteins of nuclear extracts (NE) were normalized against histone 1. NF-κB activation DNA binding was assayed by enzyme-linked immunosorbent. Values are means ± standard deviations of three independent experiments. * Compared with the control; # compared with the FD group at the respective time point by Student’s t-test at P < 0.05.

Funding

This study was funded by a 3-year grant from the National Science Council, Taiwan, Republic of China (NSC100-2320-B-030-005-MY3).

Acknowledgements

The authors acknowledge Dr Pao-Tien Chuang at University of California, San Francisco (UCSF) for his inspiration and advice on the Hh signaling project and on manuscript preparation.

Conflict of Interest Statement: None declared.

References